Vertex Pain Drug Meets Primary Endpoint in Phase 3 Trial, But Falls Short Against Opioids on Secondary Measure
-
Vertex's investigational pain drug VX-548 met its primary endpoint in a phase 3 trial, showing a notable reduction in pain over 48 hours.
-
However, VX-548 failed to meet its secondary endpoint of reducing pain more significantly than acetaminophen and an opioid.
-
VX-548 demonstrated favorable safety and tolerability in the trial with 2,400 patients.
-
Vertex is seeking FDA approval for VX-548, with Breakthrough and Fast Track Designations, to provide a non-opioid acute pain treatment option.
-
An effective, non-opioid pain drug would likely be very successful given the addiction risks of opioids.